Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit ...

Pfizer PFE reported a 2% decline in revenue and a 4% increase in adjusted EPS in 2025, and management maintained 2026 revenue guidance for $59.5 billion-$62.5 billion (between flat and a 5% decline) ...

Pfizer PFE is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which account for more than 25% of the company’s total revenues. Pfizer’s key ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...